Parsaclisib
CAS No. 1426698-88-5
Parsaclisib( INCB050465 )
Catalog No. M23581 CAS No. 1426698-88-5
Parsaclisib is a potent and selective inhibitor of PI3Kδ(IC50 of 1 nM at 1 mM ATP).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 335 | In Stock |
|
| 5MG | 306 | In Stock |
|
| 10MG | 496 | In Stock |
|
| 25MG | 806 | In Stock |
|
| 50MG | 1088 | In Stock |
|
| 100MG | 1469 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameParsaclisib
-
NoteResearch use only, not for human use.
-
Brief DescriptionParsaclisib is a potent and selective inhibitor of PI3Kδ(IC50 of 1 nM at 1 mM ATP).
-
DescriptionParsaclisib is a potent and selective inhibitor of PI3Kδ(IC50 of 1 nM at 1 mM ATP).
-
In VitroParsaclisib (0.1-3000 nM; 4 d) inhibits proliferation of MCL and DLBCL cell lines.Parsaclisib (0.1-1000 nM; 2 h) inhibits anti-IgM-induced pAKT (Ser473) in the Ramos Burkitt’s lymphoma cell line, with an IC50 of 1 nM.Parsaclisib inhibits the proliferation of human, dog, rat, and mouse primary B cells after activation of these receptors, with IC50s ranging from 0.2 to 1.7 nM. Cell Proliferation Assay Cell Line:Jeko-1, Mino, JVM2, Rec-1, Pfeiffer, SU-DHL-5, SU-DHL-6, WSU-NHL, SU-DHL-4, SU-DHL-8, and WILL-2 cells Concentration:0.1-3000 nM Incubation Time:4 days Result:Resulted in a maximal inhibition of 70-90%, with IC50s of ≤10 nM in the four MCL cell lines.Pfeiffer, SU-DHL-5, SU-DHL-6, and WSU-NHL were highly sensitive, with IC50s from 2 to 8 nM.
-
In VivoParsaclisib (10 mg/kg; oral gavage twice daily for 7-19 days) inhibits tumor growth in the BALB/c mice bearing the A20 murine lymphoma cells.Parsaclisib (0.1-10 mg/kg; p.o. twice daily) slows Pfeiffer xenograft tumor growth in a dose-dependent manner. And Parsaclisib was well tolerated.Parsaclisib (0.5-1 mg/kg; a single p.o.) inhibits pAKT (Ser473) in Pfeiffer subcutaneous mouse xenograft models. Animal Model:Female BALB/c mice (5-9 weeks) were inoculated with A20 cells Dosage:10 mg/kg Administration:Oral gavage twice daily for 7-19 days Result:Resulted in significant tumor growth inhibition (TGI).Reduced the percentage of Tregs (CD4+CD25+FOXP3+) in tumors and spleens.Increased the ratio of CD4+ and CD8+ T cells to Tregs in spleens and tumors.Decreased the number of CD4+CD44high and CD8+CD44high T cells in both spleens and tumors.
-
SynonymsINCB050465
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorPI3Kδ
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1426698-88-5
-
Formula Weight432.88
-
Molecular FormulaC20H22ClFN6O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:122 mg/mL?(281.83 mM;?Need ultrasonic)
-
SMILESCCOc(c([C@H](C)n1nc(C)c2c(N)ncnc12)c1)c([C@@H](C2)CNC2=O)c(F)c1Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Niu Shin, et al. Abstract 2671: INCB050465, a novel PI3Kδ inhibitor, synergizes with PIM protein kinase inhibition to cause tumor regression in a model of DLBCL. Cancer Research. 2015, Aug. 75(15).
molnova catalog
related products
-
AMG319
AMG319 (AMG-319) is a potent and selective PI3Kδ inhibitor with biochemical IC50 of 18 nM.
-
mTOR inhibitor 9d
mTOR inhibitor 9d is a dual inhibitor of the protein kinases mTOR and PI3K with an mTOR IC50 value of 0.31 nm, and can be used for the treatment of leukemia, skin cancer, breast cancer, lung cancer and colon cancer.
-
NIBR-17
NIBR-17 is a pan class I PI3K inhibitor. NIBR-17 inhibits PI3KKα, PI3KKβ, PI3KKγ, and PI3KKδ with IC50 of 1 nM, 9.2 nM, 9 nM, and 20 nM respectively.
Cart
sales@molnova.com